Compare Eli Lilly And Co (LLY) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Marqeta Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Marqeta Inc trades at $18.11 (market cap $1.82B). The key difference: Eli Lilly And Co is far larger — about 571.4× Marqeta Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Marqeta Inc for 44 Days on average.
| LLY | MQ | |
|---|---|---|
Market Cap | $1.04T | $1.82B |
Volume | 3,064,878 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $1.28K | $20.32 |
52-Week Low | $799.57 | $15.04 |
Typical Hold Time | 93 Days | 44 Days |
Enterprise Value | $1.09T | $1.13B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
MQ trades at $17.44, up 2.23% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 results due November 3. Revenue grew to $625M in 2025, but net income was negative. Analyst consensus is mixed, with 32% buy ratings but a price target of $11.38, below the current price. Recent news includes partnerships with BVNK for stablecoin cards and Google for wallet expansions.
MQ shows operational improvement with positive cash flow in 2025, but high valuation ratios and thin margins pose risks. The stock faces headwinds from contract renewals in Q3 2026, which may slow growth. Upside depends on sustained earnings beats and successful product expansions. Investors should weigh the bullish technicals against fundamental challenges and analyst caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
